Abstract
Multidrug therapy (MDT) has been widely accepted and used as a standard of practice in most areas of medical practice, including neuropathic pain. Because neuropathic pain is a new field of medical science and practice, standards for its treatment including MDT are still evolving. In this article, we present rationale and principals for the MDT of neuropathic pain based on our best understandings of the underlying mechanisms of the disease processes and the actions of drugs, the goal being to maximize benefits and minimize adverse effects. MDT for neuropathic pain is based on a comprehensive clinical neuropathic pain assessment and ongoing monitoring of the drug therapy’s efficacy and adverse effects, administering one drug at the time.
Similar content being viewed by others
References and Recommended Reading
Ji RR, Strichartz G: Cell signaling and the genesis of neuropathic pain. Sci STKE 2004,:reE14.
Woolf CJ: Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 2004, 74:2605–2610.Therapy based on mechanisms is the foundation for the progress of pain therapy.
Dionne RA, Bartoshuk L, Mogil J, Witter J: Individual responder analyses for pain: Does one pain scale fit all? Trends Pharmacol Sci 2005, 26:125–130.
Backonja MM, Argoff CE: Neuropathic pain: definition and implications for research and therapy. J Neuropathic Pain Symptom Palliat 2005, 1:11–17.This article presents the issues important for the development of a treatment plan for complex clinical problems, such as neuropathic pain.
Sindrup SH, Jensen TS: Pharmacologic treatment of pain in polyneuropathy. Neurology 2000, 55:915–920.
Sindrup SH, Bach FW, Madsen C, et al.: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003, 60:1284–1289.
Sindrup SH, Otto M, Finnerup NB, Jensen TS: Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005, 96:399–409.
Vinik A: Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005, 90:4936–4945.
Kalso E: Oxycodone. J Pain Symptom Manage 2005, 29:S47-S56.
Kirwin JL, Goren JL: Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy 2005, 25:396–410.
Frampton JE, Foster RH: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005, 65:111–118.
Raja SN, Haythornthwaite JA, Pappagallo M, et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59:1015–1021.Comparator studies such as this one assist in the development of MDT approaches.
Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004, 110:697–706.
Meier T, Wasner G, Faust M, et al.: Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003, 106:151–158.Combination therapies can include oral and topical agents.
Gilron I, Bailey JM, Tu D, et al.: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324–1334.This study represents an excellent example for combination studies.
White WT, Patel N, Drass M, Nalamachu S: Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003, 4:321–330.
Rice AS, Maton S, Postherpetic Neuralgia Study Group: Gabapentin in postherpetic neuralgia: a randomized, double-blind, placebo-controlled study. Pain 2001, 94:215–224.
Rowbotham M, Harden N, Stacey B, et al.: Gabapentin for the treatment of postherpetic neuralgia: a randomized, controlled trial. JAMA 1998, 280:1837–1842.
Dworkin RH, Corbin AE, Young JP Jr, et al.: Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003, 60:1274–1283.
Sabatowski R, Galvez R, Cherry DA, et al.: Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain 2004, 109:26–35.
Woolf CJ, Bennett GJ, Doherty M, et al.: Towards a mechanism-based classification of pain? Pain 1998, 77:227–229.
Martin C, Solders G, Sonnerborg A, Hansson P: Painful and non-painful neuropathy in HIV-infected patients: an analysis of somatosensory nerve function. Eur J Pain 2003, 7:23–31.Understanding neuropathic pain begins with the understanding of presenting symptoms and signs.
Otto M, Bak S, Bach FW, et al.: Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain 2003, 101:187–192.
Pappagallo M, Oaklander AL, Quatrano-Piacentini AL, et al.: Heterogeneous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology 2000, 92:691–698.
Brunelli B, Gorson C: The use of complementary and alternative medicines by patients with peripheral neuropathy. J Neurol Sci 2004, 218:59–66.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Backonja, MM., Irving, G. & Argoff, C. Rational multidrug therapy in the treatment of neuropathic pain. Current Science Inc 10, 34–38 (2006). https://doi.org/10.1007/s11916-006-0007-1
Issue Date:
DOI: https://doi.org/10.1007/s11916-006-0007-1